Phaseline

Companies › Mannkind

Mannkind: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 4 Phase 2, 2 Phase 1; Respiratory, Neurology, Metabolic and endocrine, Psychiatry; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Insulin Human
Insulin receptor agonist
INSRPhase 2Type 1 Diabetes Mellitus; Alzheimer Disease; Type 2 Diabetes; Spinal Cord Injury …Mar 2027
Nintedanib (MNKD-201)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary FibrosisDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07384052Insulin HumanPhase 1Spinal Cord InjuryNeurologyDec 2026
NCT05988632Insulin HumanPhase 1Alcohol Use DisorderPsychiatryDec 2026
NCT07224321Insulin HumanPhase 2Type 1 Diabetes MellitusRespiratoryMar 2027
NCT06072963Insulin HumanPhase 2Alzheimer DiseaseNeurologyDec 2027
NCT07679893Nintedanib (MNKD-201)Phase 2Idiopathic Pulmonary FibrosisRespiratoryDec 2027
NCT07675499Insulin HumanPhase 2Type 2 DiabetesMetabolic and endocrineMay 2029

From the company's SEC filings

Cash and short-term investments of $97m on 2026-09-30; operating cash outflow about $78m a year; runway about 15 months at that burn, to Dec 2027; 2 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PDGFRB (1) PDGFRA (1) FLT1 (1) FLT4 (1) KDR (1) INSR (1)

Companies with the same targets

Hutchmed Avalyn Pharma Betta Pharmaceuticals Chia Tai Tianqing Pharmaceutical Group AstraZeneca Jiangsu HengRui Medicine Advenchen Laboratories Merck & Co. (MSD) Takeda AO GENERIUM

Companies built like this

Rein Therapeutics aTyr Pharma Avalyn Pharma Arcturus Therapeutics Aspeya

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.